SERPINC1
Antithrombin-III
As of the edition of 20 October 2026, SERPINC1 (antithrombin-III, UniProt P01008) has 16 drugs tested at it and 26 companies on the list, 0 on route A and 7 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P01008
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Secreted
- Solved structures
- 27
- Disease areas
- Heart and blood vessels; Lungs and airways; Cancer; Infections; Urinary and reproductive; Pregnancy and women's health; Blood and lymph; Digestive system
- Registered trials of its drugs
- 529
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 15 |
| Stopped | 1 |
| Total | 16 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Enoxaparin sodium | Marketed | Phase 4 | none listed |
| Heparin | Marketed | Phase 4 | none listed |
| Dalteparin sodium | Marketed | Phase 4 | none listed |
| Fondaparinux | Marketed | Phase 4 | none listed |
| Tinzaparin | Marketed | Phase 4 | none listed |
| Nadroparin calcium | Marketed | Phase 4 | none listed |
| Heparin sodium | Marketed | Phase 4 | none listed |
| Tinzaparin sodium | Marketed | Phase 4 | none listed |
| Fitusiran | Marketed | Phase 4 | Ends 2033 |
| Semuloparin sodium | Stopped | Phase 3 | none listed |
| Bemiparin sodium | Marketed | Phase 4 | none listed |
| Danaparoid sodium | Marketed | Phase 3 | none listed |
12 of 16 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 7 |
| Engaged | 17 |
| Undetermined | 2 |
| Total on the list | 26 |
The other 23 companies at SERPINC1
In the product26 companies in all; 23 are not named here, and no score is.
See the 26 companies at SERPINC1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.